Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flumbatinib - Jiangsu Hansoh Pharmaceutical

Next Previous
X
Search
Drug Profile

Flumbatinib - Jiangsu Hansoh Pharmaceutical

Alternative Names: Flumatinib; Flumatinib mesylate - Jiangsu Hansoh Pharmaceutical; Hansoh Xinfu; HH-GV678

Latest Information Update: 10 Aug 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hansoh Pharmaceutical
  • Developer Jiangsu Hansoh Pharmaceutical; Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics; Benzamides; Piperazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Bcr-Abl tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia
  • Phase II Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 25 Jul 2023 Adverse events and efficacy data from a phase II trial in Acute lymphoblastic leukemia released by Jiangsu Hansoh Pharmaceutical
  • 31 Aug 2020 Phase-II clinical trials in Precursor cell lymphoblastic leukaemia-lymphoma in China (unspecified route) prior August 2020 (ChiCTR2100042248)
  • 12 May 2020 Preregistration for Chronic myeloid leukaemia (First-line therapy) in China (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top